-
Disc Medicine Inc NasdaqGM:IRON Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Location: 321 Arsenal Street, Watertown, MA, 02472, United States | Website: https://www.discmedicine.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
959.3M
Cash
694.7M
Avg Qtr Burn
-25.43M
Short % of Float
12.07%
Insider Ownership
10.58%
Institutional Own.
98.93%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bitopertin Details erythropoietic porphyrias, X-linked protoporphyria | NDA Submission | |
Phase 2 Data readout | ||
DISC-3405 (formerly MWTX-003) Details Polycythemia vera, Cancer, Blood cancer | Phase 2 Initiation | |
Bitopertin Details Anemia, Rare genetic disease | Phase 1/2 Update | |
GEM103 Details Age-related macular degeneration | Failed Discontinued | |
GEM103 Details Wet age-related macular degeneration , Age-related macular degeneration | Failed Discontinued |